Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-β

Gastroenterology

Volumn 120, Issue 7, 2001, Pages 1784-1800

  Okuno, Masataka ^a   Akita, Kuniharu ^a   Moriwaki, Hisataka ^a   Kawada, Norifumi ^b   Ikeda, Kazuo ^b   Kaneda, Kenji ^b   Suzuki, Yasuhiro ^c   Kojima, Soichi ^c  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAMOSTAT MESILATE; MUSCLE PROTEIN; PLASMIN; PROTEINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG STRUCTURE; IN VIVO STUDY; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL;

EID: 0035022130     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.24832     Document Type: Article

References (61)

1. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury
2. Molecular mechanisms of liver fibrogenesis - A homage to the role of activated fat-storing cells
3. Modulation of transforming growth factor β receptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo
4. Hepatic fibrosis - Therapeutic strategies
5. Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy
6. Transforming growth factor β in tissue fibrosis
7. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation
8. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice
9. Retinoic acid-stimulated liver stellate cells suppress the production of albumin from parenchymal cells via TGF-β
10. Blockade of type β transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat
11. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats
12. Hepatocyte growth factor gene therapy of liver cirrhosis in rats
13. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor β type II receptor: A potential new therapy for hepatic fibrosis
14. TGF-β: From latent to active
15. Thrombospondin-1 is a major activator of TGF-β1 in vivo
16. The integrin αvβ6 binds and activates latent TGFβ1: A mechanism for regulating pulmonary inflammation and fibrosis
17. Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF-β in liver stellate cells
18. Increased 9, 13-di-cis-retinoic acid in rat hepatic fibrosis: Implication for a potential link between retinoid loss and TGF-β mediated fibrogenesis in vivo
19. 9, 13-di-cis-Retinoic acid induces the production of tPA and activation of latent TGF-β via RARα in a human liver stellate cell line, IL90
20. Insulinlike growth factor-II/mannose 6-phosphate receptor is expressed on CCI4-exposed rat fat-storing cells and facilitates activation of latent transforming growth factor-β in cocultures with sinusoidal endothelial cells
21. Insulin-like growth factor II/mannose 6-phosphate-receptor expression in liver and serum during acute CCI4 intoxication in the rat
22. Protease inhibitors suppress TGF-β generation by hepatic stellate cells
23. Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r, and C1 esterase
24. Clinical effects of camostat in chronic pancreatitis
25. Pharmaceutical development for treating pancreatic diseases
26. Effect of oral protease inhibitor administration on gallbladder motility in patients with mild chronic pancreatitis
27. Effect of camostat in the treatment of reflux esophagitis after gastrectomy: An experimental study in rats and a pilot clinical study
28. Jejunal pouch with nerve preservation and interposition after total gastrectomy
29. Contribution of immune response to the hepatic fibrosis induced by porcine serum
30. Report of the American Institute of Nutrition ad hoc committee on standards for nutritional studies
31. An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct
32. Regulation of gastric epithelial cell growth by Helicobacter pylori: Evidence for a major role of apoptosis
33. Inhibition of myofibroblastic transformation of cultured rat hepatic stellate cells by methylxanthines and dibutyryl cAMP
34. Specificity in transforming growth factor beta-induced transcription of the plasminogen activator inhibitor-1 gene: Interactions of promoter DNA, transcription factor muE3, and Smad proteins
35. Type 1 plasminogen activator inhibitor gene: Functional analysis and glucocorticoid regulation of its promoter
36. Physical interaction between retinoic acid receptor and Sp1: Mechanism for induction of urokinase by retinoic acid
37. Retinoids potentiate transforming growth factor-β activity in bovine endothelial cells through up-regulating the expression of transforming growth factor-β receptors
38. Evaluation of cationic liposome suitable for gene transfer into pregnant animals
39. Bovine urokinase-type plasminogen activator and its receptor: Cloning and induction by retinoic acid
40. Storage of vitamin A in extrahepatic stellate cells in normal rats
41. Lipoprotein (a) inhibits the generation of transforming growth factor β: An endogenous inhibitor of smooth muscle cell migration
42. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin
43. Specificity, diversity, and regulation in TGF-beta superfamily signaling
44. The plasminogen-activating system in hepatic stellate cells
45. Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation
46. Production of tissue-type plasminogen activator (t-PA) and type-1 plasminogen activator inhibitor (PAI-1) in mildly cirrhotic rat liver
47. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: Role of stellate cells
48. Control of scarring in adult wounds by neutralizing antibody to transforming growth factor β
49. Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix
50. Negative regulation of transforming growth factor-β by the proteoglycan decorin
51. Inhibition of experimentally-induced liver cirrhosis in rats by a nonpeptidic mimetic of the extracellular matrix-associated Arg-Gly-Asp epitope
52. Inhibition of integrin signaling with Arg-Gly-Asp motifs in rat hepatic stellate cells
53. Inhibition of rat hepatic lipocyte activation in culture by interferon-γ
54. Interferon alpha and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture
55. Interferon gamma treatment prevents procollagen gene expression without affecting transforming growth factor-β1 expression in pig serum-induced rat liver fibrosis in vivo
56. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells
57. Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis
58. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis
59. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats
60. The prolyl 4-hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient L-amino acid-defined diet
61. Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation